The Effects of Apkc Inhibitors on Cell Proliferation and Cell Viability in Mantle Cell Lymphoma
Mentor Information
Mildred Acevedo-Duncan (Chemistry)
Description
Mantle Cell Lymphoma (MCL) is a rare and aggressive Non-Hodgkin’s Lymphoma subtype. It is currently incurable, however targeted therapy has proven to be effective in MCL. The targets of interest in this study are the Atypical Protein Kinases (aPKC) PKC Zeta and PKC Iota. PKC Zeta and PKC Iota have played a role in cell proliferation and survival in a variety of different cancer types, including lymphoma. Current drugs that inhibit aPKCs are ICA-1 and Z-Stat. ICA-1 targets PKC Iota and Z-Stat targets PKC Zeta. This study investigated the effects of ICA-1 and Z-stat on cell proliferation and cell viability in MCL cell lines Jeko-1 and Granta-519. Jeko-1 and Granta-519 were treated with increasing concentrations of either ICA-1 or Z-Stat over a 72-hour period. The cells were counted using the trypan blue staining method at 72 hours. When treated with either Z-Stat or ICA-1, both cell lines showed a decrease in cell numbers with little to no change in cell viability, suggesting that the drugs could have a cytostatic effect on these cell lines. The results of this study suggest that Z-Stat and ICA-1 could be viable treatment options for MCL patients and further study into the role of aPKCs in MCL should be conducted.
The Effects of Apkc Inhibitors on Cell Proliferation and Cell Viability in Mantle Cell Lymphoma
Mantle Cell Lymphoma (MCL) is a rare and aggressive Non-Hodgkin’s Lymphoma subtype. It is currently incurable, however targeted therapy has proven to be effective in MCL. The targets of interest in this study are the Atypical Protein Kinases (aPKC) PKC Zeta and PKC Iota. PKC Zeta and PKC Iota have played a role in cell proliferation and survival in a variety of different cancer types, including lymphoma. Current drugs that inhibit aPKCs are ICA-1 and Z-Stat. ICA-1 targets PKC Iota and Z-Stat targets PKC Zeta. This study investigated the effects of ICA-1 and Z-stat on cell proliferation and cell viability in MCL cell lines Jeko-1 and Granta-519. Jeko-1 and Granta-519 were treated with increasing concentrations of either ICA-1 or Z-Stat over a 72-hour period. The cells were counted using the trypan blue staining method at 72 hours. When treated with either Z-Stat or ICA-1, both cell lines showed a decrease in cell numbers with little to no change in cell viability, suggesting that the drugs could have a cytostatic effect on these cell lines. The results of this study suggest that Z-Stat and ICA-1 could be viable treatment options for MCL patients and further study into the role of aPKCs in MCL should be conducted.
